Expression of IL-34 correlates with macrophage infiltration and prognosis of diffuse large B-cell lymphoma.
CSF1R
DLBCL
IL‐34
Macrophages
M‐CSF
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2019
2019
Historique:
received:
16
04
2019
revised:
16
07
2019
accepted:
16
07
2019
entrez:
17
8
2019
pubmed:
17
8
2019
medline:
17
8
2019
Statut:
epublish
Résumé
Infiltration of macrophages through the tyrosine kinase receptor CSF1R is a poor prognosis factor in various solid tumors. Indeed, these tumors produce CSF1R ligand, macrophage colony-stimulating factor (M-CSF) or interleukin-34 (IL-34). However, the significance of these cytokines, particularly, the newly discovered IL-34 in haematological malignancies, is not fully understood. We therefore analysed the role of IL-34 in diffuse large B-cell lymphoma (DLBCL), the most common subtype of malignant lymphoma. We analysed formalin-fixed paraffin-embedded lymphoma tissues of 135 DLBCL patients for the expression of IL-34 and the number of macrophages, and the survival of these patients. The expression of IL-34 in DLBCL cell lines and the activity of IL-34 to induce the migration of monocytic cells were also characterised. Several lymphoma tissues showed a clear IL-34 signal, and such signal was detectable in 36% of patients. DLBCL cell lines also expressed IL-34. Interestingly, the percentage of IL-34 Our results raise the possibility that IL-34 in lymphoma tissues of DLBCL patients recruits monocytes, leading to the higher number of macrophages in the tissues and poor prognosis of patients. IL-34 may be an additional therapeutic target of DLBCL.
Identifiants
pubmed: 31417675
doi: 10.1002/cti2.1074
pii: CTI21074
pmc: PMC6691654
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1074Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nature. 2000 Feb 3;403(6769):503-11
pubmed: 10676951
Blood. 2002 Jan 1;99(1):111-20
pubmed: 11756160
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16078-83
pubmed: 16249345
Nature. 2006 May 4;441(7089):106-10
pubmed: 16572121
Mol Cancer Ther. 2006 Nov;5(11):2634-43
pubmed: 17121910
Cell Tissue Res. 2007 Nov;330(2):291-302
pubmed: 17874251
Science. 2008 May 9;320(5877):807-11
pubmed: 18467591
Pathol Int. 2008 Aug;58(8):529-32
pubmed: 18705775
N Engl J Med. 2008 Nov 27;359(22):2313-23
pubmed: 19038878
Cell Death Differ. 2010 Dec;17(12):1917-27
pubmed: 20489731
J Leukoc Biol. 2010 Sep;88(3):495-505
pubmed: 20504948
Cell Commun Signal. 2010 Sep 07;8:20
pubmed: 20822514
Am J Clin Pathol. 2011 Jan;135(1):54-61
pubmed: 21173124
Cancer Sci. 2011 Jul;102(7):1424-31
pubmed: 21453387
Med Oncol. 2012 Dec;29(4):2317-22
pubmed: 22198695
Histopathology. 2012 May;60(6):924-32
pubmed: 22321065
Nat Immunol. 2012 Jun 24;13(8):753-60
pubmed: 22729249
Cancer Sci. 2012 Dec;103(12):2165-72
pubmed: 22957741
Immunity. 2012 Dec 14;37(6):1050-1060
pubmed: 23177320
Nature. 2013 Apr 25;496(7446):445-55
pubmed: 23619691
J Biol Chem. 2013 Jul 26;288(30):21972-86
pubmed: 23744080
Nat Rev Clin Oncol. 2014 Jan;11(1):12-23
pubmed: 24217204
Leuk Lymphoma. 2014 Nov;55(11):2466-76
pubmed: 24397616
Hematol Oncol. 2015 Jun;33(2):110-2
pubmed: 24711044
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Haematologica. 2015 Feb;100(2):238-45
pubmed: 25381134
Haematologica. 2015 Mar;100(3):363-9
pubmed: 25425693
Int J Cancer. 2015 Jul 1;137(1):73-85
pubmed: 25471534
Blood. 2015 Jan 1;125(1):22-32
pubmed: 25499448
Nat Cell Biol. 2015 Feb;17(2):170-82
pubmed: 25580734
Biochim Biophys Acta. 2015 Apr;1855(2):123-30
pubmed: 25595840
Haematologica. 2015 Feb;100(2):143-5
pubmed: 25638802
Biochim Biophys Acta. 2015 May;1853(5):1010-21
pubmed: 25662098
Semin Hematol. 2015 Apr;52(2):67-76
pubmed: 25805586
Biomed Res Int. 2015;2015:484537
pubmed: 25984532
Curr Opin Pharmacol. 2015 Aug;23:45-51
pubmed: 26051995
J Immunol. 2015 Nov 1;195(9):4341-50
pubmed: 26416279
Hepatology. 2016 May;63(5):1560-75
pubmed: 26754294
Cancer Res. 2016 Oct 15;76(20):6030-6042
pubmed: 27550451
Cancer Sci. 2016 Nov;107(11):1696-1704
pubmed: 27564404
Histopathology. 2017 Mar;70(4):595-621
pubmed: 27775850
Oncotarget. 2017 Jan 17;8(3):5414-5425
pubmed: 28036275
Cancer Cell. 2017 Jan 9;31(1):64-78
pubmed: 28073005
Curr Top Dev Biol. 2017;123:229-275
pubmed: 28236968
J Clin Exp Hematop. 2017;57(1):31-36
pubmed: 28679964
J Clin Exp Hematop. 2018;58(4):152-160
pubmed: 30541986
Blood Adv. 2019 Feb 26;3(4):541-551
pubmed: 30782613
J Immunol. 1988 Jul 15;141(2):575-9
pubmed: 3290341